Catálogo de monumentos megalíticos en Navarra. Homenaje a Francisco Ondarra (1925-2005)

Este trabajo pretende llenar el vacío que existe actualmente en relación con el megalitismo de esta región. Se da a conocer un catálogo actualizado, de más de 1500 megalitos, resultado de una prospección y revisión de datos intensa llevada a cabo por los firmantes del mismo durante años. El listado que aquí se incluye es paso previo a la publicación individualizada de las fichas de todos estos monumentos, como contribución a la Carta Arqueológica de Navarra

Distinguishing Local and Global Influences on Galaxy Morphology: A Hubble Space Telescope Comparison of High and Low X-Ray Luminosity Clusters.

We present a morphological analysis of 17 X-ray-selected clusters at z ~ 0.25, imaged uniformly with the Hubble Space Telescope Wide Field Planetary Camera 2 (WFPC2). Eight of these clusters comprise a subsample selected for their low X-ray luminosities (lesssim1044 ergs s-1), called the low-LX sample. The remaining nine clusters comprise a high-LX subsample with LX > 1045 ergs s-1. The two subsamples differ in their mean X-ray luminosity by a factor of 30 and span a range of more than 300. The clusters cover a relatively small range in redshift (z = 0.17-0.3, σz/z ~ 0.15), and the data are homogeneous in terms of depth, resolution (0farcs17 = 1 himg1.gif kpc at z = 0.25), and rest wavelength observed, minimizing differential corrections from cluster to cluster. We fit the two-dimensional surface brightness profiles of galaxies down to very faint absolute magnitudes, M702 ≤ -18.2 + 5 log h50 (roughly 0.01Limg2.gif) with parametric models, and quantify their morphologies using the fractional bulge luminosity (B/T). Within a single WFPC2 image, covering a field of ~3' (1 himg1.gif Mpc at z = 0.25) in the cluster center, we find that the low-LX clusters are dominated by galaxies with low B/T (~0), while the high-LX clusters are dominated by galaxies with intermediate B/T (~0.4). We test whether this difference could arise from a universal morphology-density relation due to differences in the typical galaxy densities in the two samples. We find that small differences in the B/T distributions of the two samples persist with marginal statistical significance (98% confidence based on a binned χ2 test) even when we restrict the comparison to galaxies in environments with similar projected local galaxy densities. A related difference (also of low statistical significance) is seen between the bulge-luminosity functions of the two cluster samples, while no difference is seen between the disk luminosity functions. From the correlations between these quantities, we argue that the global environment affects the population of bulges, over and above trends seen with local density. On the basis of this result, we conclude that the destruction of disks through ram pressure stripping or harassment is not solely responsible for the morphology-density relation and that bulge formation is less efficient in low-mass clusters, perhaps reflecting a less rich merger history

TGF-β in vascular pathobiology

The transforming growth factor (TGF)-β superfamily includes 32 cytokines that tightly regulate vascular cell behaviour such as proliferation, migration, apoptosis, differentiation and extracellular matrix (ECM) maintenance, production and remodelling. Superfamily ligands signal via distinct type I and type II transmembrane serine/threonine kinase receptors activating canonical receptor-regulated (R)-s-mothers against decapentaplegic (SMAD) signalling and non-canonical signalling pathways. Normal vascular morphogenesis and homeostasis depend on intact TGF-β superfamily signalling. Genetic studies have demonstrated that defects in genes encoding TGF-β superfamily members predispose or are causally linked to certain hereditary vascular disorders (HVDs) such as hereditary haemorrhagic telangiectasia (HHT), hereditary pulmonary arterial hypertension (HPAH) and Loeys-Dietz syndrome (LDS). These discoveries have led to a better understanding of HVD pathogenesis giving rise to novel drug treatment strategies continuously improving life expectancy and the quality of life of affected patients. In addition, recent studies have discovered that the type I receptor activin-like kinase (ALK)1 and the type III co-receptor endoglin (ENG) promote tumour angiogenesis prompting the development of the ALK1 ligand trap dalantercept, the neutralising ALK1 antibody PF-03446962 and the monoclonal ENG antibody carotuximab. These novel anti-angiogenic cancer drugs have been or are currently being tested in phase I, II and III clinical trials for patients with advanced solid tumours